MedTrace Logo

Branched-chain Amino Acid (BCAA) on Progression of Advanced Liver Disease

NCT02837302 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 1470

Last updated 2016-10-31

No results posted yet for this study

Summary

Protein-calorie malnutrition is frequently observed in patients with advanced liver cirrhosis. There have been continued interests in potential benefits of long-term oral branched-chain amino acid supplement in improving severity of liver disease. However, there are limited evidences in literature. The aim of this study is to evaluate the efficacy of oral branched-chain amino acid in patients with advanced liver cirrhosis.

Conditions

Interventions

DRUG

Livact

Daily dose of 12.45g of branched-chain amino acid containing 3.4g of L-valine, 5.7g of L-leucine, and 2.9g of L-isoleucine over 6 months.

Sponsors & Collaborators

  • Samil Pharmaceutical Co., Ltd.

    collaborator INDUSTRY

  • Kyungpook National University Hospital

    lead OTHER

Principal Investigators

  • Won Young Tak, M.D., Ph.D. · Kyungpook national university hospital, department of internal medicine

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2017-12-31
Completion
2018-06-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02837302 on ClinicalTrials.gov